## ASO VISUAL ABSTRACT


## ASO Visual Abstract: Switching Perfusion Agents for Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy, Surgical Dogma or Evidence-Based Practice?

Christopher W. Mangieri, MD , Cristian D. Valenzuela, MD, Ian B. Solsky, MD, Richard A. Erali, MD, Konstantinos I. Votanopoulos, MD, PhD, Perry Shen, MD, and Edward A. Levine, MD

Division of Surgical Oncology, Wake Forest Baptist Health Medical Center, Winston-Salem, NC

In this retrospective review of our institutional registry involving repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) cases (https://doi.org/10.1245/s10434-022-12392-5), we compared cases that underwent a perfusion agent switch versus those cases with no switch. The primary outcome was survival as

measured by overall survival (OS) and disease-free survival (DFS). Subgroup analysis was performed on the basis of primary etiology. Study findings revealed no survival benefit with switching perfusion agents. Analysis suggests that the practice of perfusion switch is ineffective.



**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© Society of Surgical Oncology 2022 Published Online: 4 September 2022

C. W. Mangieri, MD

e-mail: elevine@wakehealth.edu